Assuntos
Substituição de Aminoácidos , Cromograninas/genética , Subunidades alfa Gs de Proteínas de Ligação ao GTP/genética , Tumor de Células de Leydig/genética , Mutação de Sentido Incorreto , Neoplasias Ovarianas/genética , Mutação Puntual , Virilismo/etiologia , Idoso de 80 Anos ou mais , Androgênios/metabolismo , Carcinoma de Células Renais , AMP Cíclico/metabolismo , Evolução Fatal , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Neoplasias Renais , Tumor de Células de Leydig/complicações , Tumor de Células de Leydig/secundário , Pessoa de Meia-Idade , Neoplasias Primárias Múltiplas , Neoplasias Ovarianas/complicações , Neoplasias Gástricas/diagnóstico por imagem , Neoplasias Gástricas/secundárioRESUMO
OBJECTIVE: The standard treatment for primary hypothyroidism is replacement with levothyroxine to achieve a thyroid-stimulating hormone (TSH) level within the normal range, (0.45-4.5 mIU/L), which is known to prevent complications including weight gain. While the normal TSH range includes the 95% confidence intervals, it is not known if there is an association between weight and TSH within this interval in treated hypothyroid patients. METHODS: We conducted a retrospective analysis of patients treated within the Cooper Health System from January 1 to August 31, 2014. A sample of 245 treated hypothyroid patients and 162 euthyroid controls were studied. Data collected included age, sex, race/ethnicity, height, weight, levothyroxine dose, and diabetes and smoking history. RESULTS: Hypothyroid and control groups were similar in height, weight, body mass index (BMI), and the number of patients with diabetes. There were more females, Caucasians, and nonsmokers in the hypothyroid group. The average TSH was slightly higher in the treated hypothyroid patients versus nonhypothyroid controls (median 1.87 vs. 1.55, P<.01). There was no significant relationship between TSH and BMI in the treated hypothyroid patients or the euthyroid controls. CONCLUSION: Since no significant relationship was found between BMI and TSH in treated hypothyroidism, there may be no weight reduction benefit gained by adjusting TSH to the lower end of normal range. Patients should be counseled that properly treated hypothyroidism is unlikely to contribute to weight gain. Other treatments such as nutrition and exercise counseling should be offered instead.